Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

2020 Year in Review - Neuroendocrine Tumors

Patient-reported outcomes data of the XERMELO Patient Registry indicate that patients with neuroendocrine tumors (NETs) experiencing carcinoid syndrome (CS) reported improvement in CS symptom control and satisfaction with telotristat ethyl (TE) treatment, as well as reduced activity impairment and work productivity losses after 6 months of treatment.
Findings of a population-based retrospective cohort study indicate that the risk for cancer-specific death exceeds the risk for noncancer death; however, patients with nonmetastatic neuroendocrine tumors (NETs) may have a higher risk for noncancer deaths.
Results of a retrospective analysis of first-line chemotherapy regimens indicate that non–platinum/etoposide regimens may provide a significant progression-free survival (PFS) benefit versus platinum/etoposide regimens for patients with grade 3 neuroendocrine tumors (NETs).
A retrospective analysis of a large database of grade 3 gastroenteropancreatic (GEP) neuroendocrine carcinomas (NECs) identified clinically relevant prognostic factors that could potentially inform clinical decisions in this setting.
Preliminary results of an ongoing dose-escalation and expansion phase 1 (Duet 1; NCT03411915) trial indicate that the anti–somatostatin receptor type 2 (SSTR2) × anti-CD3 bispecific antibody XmAb18087 was well-tolerated and accompanied by sustained T-cell activation in patients with advanced neuroendocrine tumors (NETs).
Results of the prospective phase 2 ATLANT study indicate that lanreotide autogel (LAN) plus temozolomide (TMZ) combination therapy was efficacious and well-tolerated in patients with progressive thoracic neuroendocrine tumors (NETs).
Results of a placebo-controlled, randomized phase 2 trial indicate that maintenance treatment with lanreotide autogel (LAN) following first-line treatment may provide clinical benefit in aggressive grade 1 and 2, well-differentiated, duodeno-pancreatic neuroendocrine tumors (NETs).
Findings of a comparative retrospective analysis indicate that first-line octreotide long-acting release (LAR) and lanreotide treatment was associated with similar progression-free survival (PFS) and biochemical response in patients with metastatic, well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Real-world data from a retrospective analysis of octreotide long-acting release (LAR) dosing patterns on treatment persistence in patients with symptomatic metastatic neuroendocrine tumors (NETs) indicate that physician experience and treatment at tertiary centers has a significant impact on dose selection and treatment persistence.
Results of the randomized, open-label phase 2 Australasian Gastrointestinal Trials Group CONTROL NET study indicate that capecitabine/temozolomide (CAPTEM) plus 177Lu-octreotate peptide receptor radionuclide therapy (PPRT) combination treatment was active and well-tolerated compared with CAPTEM or PPRT alone in patients with pancreatic neuroendocrine tumors (pNETs) and updated midgut neuroendocrine tumors (mNETs).
Page 2 of 4
Results 11 - 20 of 31